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Abstract
Sepsis is systemic inflammatory response syndrome due to a documented or sus-
pected infection. Causative agents of sepsis include group B streptococcus, Escherichia 
coli, and Listeria monocytogenes in infants younger than 2 months, and community‐
acquired organisms. Bacteremia may ensue in patients whose defense mechanisms 
have become vulnerable due to many factors. Sepsis and septic shock can be viewed 
as clinical pictures, which develop as consequences of proinflammatory processes/
cytokines leading to a state that cannot be restrained by anti‐inflammatory processes/
cytokines. As yet, a cytokine, which is uniquely associated with severe sepsis and 
septic shock and can be used as a biomarker, has not been discovered. Sepsis is a 
cytokine storm, which may adversely affect almost any organ system. Whether there 
is an association between the severity of sepsis or septic shock and cytokine gene 
polymorphisms is an important field of study. Mottled skin and prolongation of cap-
illary refill time may help the physician recognize septic shock before hypotension 
emerges. The management of severe sepsis and septic shock involves (1) the hemo-
dynamic support, (2) inotropes, vasopressors, and vasodilators, (3) antimicrobial 
therapy, (4) transfusions, and (5) corticosteroids as indicated. Hospital mortality of 
pediatric sepsis is 2–10%.
Keywords: sepsis, pediatrics, cytokines, sepsis‐associated encephalopathy, systemic 
inflammatory response syndrome, neonatal sepsis
1. Introduction
Although sepsis can affect any individual at any time during her/his lifetime, it is more apt to 
occur and be destructive at the extremes of life, the very old and the very young.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
It is sometimes referred to as “blood poisoning” in anglophone countries and in various man-
ners elsewhere (e.g., “microbe in blood” in Turkey). The sepsis is the body’s deadly response 
to infection. Once sets in, sepsis can progress to septic shock and death if left untreated. One‐
third of people who develop sepsis die worldwide. These deaths occur more frequently in 
economically developing countries [1].
This chapter deals with pediatric sepsis with much greater emphasis on beyond neonatal 
period.
2. Definitions
Systemic inflammatory response syndrome (SIRS) is defined as two or more of the following 
items, one of which has to be the one marked with an asterisk (*) [2]:
1. Body core temperature of higher than 38.5°C or lower than 36°C*.
2. Except leukopenia caused by chemotherapy, a leukocyte count exceeding or lower than 
normal limit for age or immature leukocyte count above 10% of total leukocyte count*.
3. Abnormal heart rate:
(a) In children 1 year of age and over
• Average heart rate in excess of two standard deviations from the age normal in the 
absence of external stimuli, long‐term drug use, or painful stimuli
• Persistent elevation in heart rate in 24 h without any other explanation
(b) In children less than 1 year of age
• Average heart rate below 10th percentile for age in the absence of external vagal 
stimulus, beta‐blocker, or congenital heart disease
• Persistent depression in heart rate in half an hour without any other explanation
4. Average respiratory rate of more than two standard deviations above normal for mechani-
cal ventilation that is being carried out for an acute process irrelevant of general anesthesia 
or an underlying neuromuscular disease.
Sepsis is SIRS due to a documented or suspected infection [2–5].
Organ dysfunction definitions are explained below:
1. If at least one of the following items is present despite isotonic intravenous fluid bolus (≥40 
mL/kg in 1 h), this is called cardiovascular dysfunction [2]:
(a) Criteria for drop in blood pressure:
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• Blood pressure is below fifth percentile for age OR.
• Systolic blood pressure below two standard deviations of normal for age.
(b) Vasoactive drugs required for maintaining normal blood pressure (5 μg/kg/min dopa-
mine or dobutamine of any dosage, epinephrine, or norepinephrine).
(c) Presence of more than two of the following items:
• Unexplained metabolic acidosis with a base deficit of more than 5 mmol/L.
• Arterial lactate concentration of more than two times the upper limit.
• Urine output of less than 0.5 mL/kg/h.
• Capillary refill time of more than 5 s.
• The difference between core and peripheral temperature of more than 3°C.
2. If at least one of the following items is present, this is called respiratory dysfunction [2]:
(a) Arterial oxygen partial pressure (PaO2)/inspired oxygen fraction (FiO2) ratio of less than 300 in the absence of pulmonary disease or cyanotic heart disease.
(b) Initial measurement of arterial carbon dioxide partial pressure (PaCO2) above 65 Torr or 20 mmHg.
(c) Proven requirement for maintaining the saturation at or above 92% or FiO2 of more than 50%.
(d) Nonelective invasive or noninvasive mechanical ventilation requirement.
3. If at least one of the following items is present, this is called neurological dysfunction [2]:
(a) Glasgow Coma Score of 11 or less.
(b) Acute change in mental status together with a drop of Glasgow Coma Score of three or 
more points from abnormal baseline value.
4. If at least one of the following items is present, the situation is called hematological dys-
function [2]:
(a) International normalized ratio (INR) above 2.
(b) Platelet count below 80,000/μL or has decreased 50% from the highest value recorded 
in the last 3 days (for chronic hematology‐oncology patients).
5. Renal dysfunction is serum creatinine concentration of two times the upper limit for nor-
mal or more or twofold increase in baseline serum creatinine [2].
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6. The presence of at least two of the following items is called liver dysfunction [2]:
(a) Alanine transaminase (ALT) concentration of two times the upper limit for age.
(b) Total bilirubin concentration of 4 mg/dL or more (not applicable for newborns).
For establishing the diagnosis of acute respiratory distress syndrome (ARDS), the following 
criteria should be met [2]:
• PaO2/FiO2 ratio <200 mmHg.
• Bilateral infiltrates on chest X‐ray.
• Acute onset.
• No sign of left heart failure present.
If, in addition to sepsis, there is cardiovascular organ dysfunction, ARDS, or two or more 
other organ dysfunctions, this situation is called severe sepsis [2].
3. Causative agents
Sepsis may be a consequence of infections due to bacteria, viruses, fungi, or parasites. 
Causative agents of sepsis include group B streptococcus, Escherichia coli, Listeria monocyto-
genes in infants younger than 2 months of age, and community‐acquired organisms like S. 
pneumoniae and Neisseria meningitidis in children of 1–2 years. In a Canadian study of 6‐year 
duration, the most common pathogens in bloodstream infections of childhood were S. pneu-
moniae, Staphylococcus aureus, and E. coli [6].
4. Pathophysiology
The site of infection, as the cause of sepsis, varies according to age. In infants, it is usually 
primary bacteremia. There is respiratory tract infection in nearly half of older children with 
sepsis [7].
Since sepsis is defined as SIRS, or in other words, pathological changes in body tempera-
ture, heart, or respiratory rates, and leukocyte count in the presence of proven or suspected 
 infection, it would be prudent that we review the pathogeneses of the components of SIRS 
and infection that form sepsis and changes due to organ dysfunction in severe sepsis sepa-
rately [2, 8].
4.1. Formation of infection
One of the most important clinical situations causing sepsis and septic shock is bacteremia. 
Bacteria must pass through the dermal or mucosal barrier in order that bacteremia takes place. 
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The pathogenesis of bacteremia is closely associated with the self‐defense of the host and the 
characteristics of the bacteria. Organisms like S. pneumoniae, N. meningitidis and Haemophilus 
influenzae type b, which form a part of nasopharyngeal flora, cause bacteremia by overcoming 
mucosal defense systems with the aid of facilitating factors like upper respiratory infections. 
N. meningitidis is taken into the cylindrical epithelial cell with phagocytosis. After traversing 
the cytoplasm in the phagosome, it passes into subepithelial tissues. H. influenzae type b passes 
into subepithelial tissues by clinging to the epithelial cell and loosing the intercellular tight 
junctions making its way toward pharyngeal capillaries. S. pneumoniae attaches to specific 
receptors by means of which it enters the cell. The number of platelet‐activating factor recep-
tors located on surfaces of respiratory epithelial cells increases during viral infections. These 
receptors serve as attachment sites for pneumococci. Gram‐negative organisms that are a part 
of gut flora also attach to specific receptors. Pili and adhesins on the microorganism surface 
play a pivotal role in this attachment. Pili were also shown to be important in the pathogenesis 
of sepsis caused by Streptococcus pyogenes, Group B streptococcus, and S. pneumoniae [9].
Bacteremia may ensue in patients whose defense mechanisms have become vulnerable due to 
many factors. The examples are as follows:
• With the intubation of an intensive care patient, protease activity increases whereas cell‐
bound fibronectin diminishes rendering cell surface receptors “sheathless,” which make 
them ideal binding sites for predominantly Gram‐negative bacteria of gut flora [9].
• Viridans streptococci, elements of oral flora, may cause bacteremia in neutropenic children 
who have severe oral mucositis and receiving antineoplastic chemotherapy.
• Gram‐negative gut bacteria cause bacteremia by traversing the gut mucosa (translocation), 
whose integrity has been disrupted by antineoplastic drugs.
• Staphylococci, thanks to their ability to adhere to hard surfaces, cause catheter‐related bac-
teremia by colonizing in catheter lumina.
4.2. The process of cytokine synthesis
The word “cytokine” is made up of two Greek words, “cyto‐” (cell) and kinos (movement). 
The cytokine concept was introduced to scientific world by Barry Bloom and John David, who, 
being unaware of each other’s similar research, discovered a cytokine, known as macrophage 
migration inhibitor factor today. Although cytokines were once classified as lymphokines, 
interleukins, and chemokines, according to their functions, and target and release sites, such a 
classification is avoided due to the abundance and substitution characteristics of cytokines [10].
Every cytokine has a corresponding cell surface receptor, with the stimulation of which begin 
signaling cascades, as a consequence of which some genes are upregulated or downregulated. 
In the end, either other cytokines or cell receptors for various molecules are synthesized, or 
the rate of synthesis of these substances decreases [10].
Sepsis and septic shock can be viewed as clinical pictures, which develop as consequences of pro-
inflammatory processes/cytokines leading to a state that cannot be restrained by anti‐ inflammatory 
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processes/cytokines (Table 1). The human body responds in a pathological manner to infec-
tion, which is a pathological situation itself. The occurrence of sepsis or immune compromise 
depends on whether systemic inflammatory response or its opposite end, compensatory anti‐
inflammatory response syndrome, predominates the inner environment as a response to infec-
tion. Compensatory anti‐inflammatory response syndrome is a clinical entity, which progresses 
primarily with T‐helper depression due to catecholamine discharge and apoptosis of splenic 
B‐ lymphocytes [11].
When the causative organism enters the body, nonspecific (innate) immune system is stimu-
lated. Mammals perceive the pathogen by means of pattern‐recognition receptors, the most 
important and evolutionally the oldest of which are Toll‐like receptors (TLRs), found in 
insects, plants, and mammals. TLRs are transmembrane proteins, so‐called because of their 
similarity to a product protein of the gene Toll, which is named after the remark (“Das ist ja 
toll!” (“That’s really cool!”)) by Nobel Prize in Physiology or Medicine winner (1995) Christina 
Nüsslein‐Volhard, who has reportedly shouted out as so in surprise when she realized a 
Drosophila melanogaster (common fruit fly) had assumed an amazing appearance as a result of 
Proinflammatory Anti‐inflammatory
TNF‐α IL‐1Ra
IL1b, IL‐2, IL‐6, IL‐8, IL‐15 IL‐4
Neutrophil elastase IL‐10
IFN‐γ IL‐13
Thromboxane Type II IL‐1 receptor
Platelet‐activating factor Transforming growth factor‐b
Vasoactive neuropeptides Adrenaline
Phospholipase A2 Soluble TNF‐α receptors
Plasminogen activator inhibitor‐1 Leukotriene B4‐receptor antagonist
Prostaglandins
Prostacyclin
Free radicals
Soluble adhesion molecules
Tyrosine kinase
Protein kinase
H2S
NO
High mobility group box 1 protein
TNF: tumor necrosis factor, IL: interleukin, IFN: interferon.
Table 1. Major proinflammatory and anti‐inflammatory mediators [12].
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polymorphism of one of its proteins [13]. Transmembrane proteins have their extracellular, 
transmembrane, and intracellular parts. Humans have at least 10 different TLRs [14]. TLRs 
are found in abundance on leukocytes, macrophages, and some kinds of endothelial cells 
[11]. It is noteworthy that some TLRs are found on cytoplasmic membrane and some on the 
membrane of endocytic vesicules. These receptors recognize many organisms, from bacteria 
to fungi, and from protozoa to viruses. Although a part of nonspecific immune system, TLRs 
vary with respect to the patterns concerning the component of the organism they recognize. 
For instance, whereas TLR4 is unique in recognizing lipopolysaccharide of Gram‐negative 
bacteria, mannan of Candida albicans, and glucuronoxylomannan of Cryptococcus neoformans, 
glycosylphosphatidylinositol moieties of Plasmodium falciparum are recognized by either TLR4 
or TLR2. Hemozoin of P. falciparum is exclusively recognized by TLR9 [15].
Stimulated TLRs cause many protein kinases to be phosphorilized, in other words, become 
active. Reactions of these highly complex biochemical pathways take place in cytosol or 
endosome. Some of the biochemical pathways are dependent on a mediator molecule named 
MyD88, and some are not. For example, proinflammatory cytokines in sepsis and septic 
shock are released in a MyD88‐dependent pathway. The end products of these pathways 
(nuclear factor kappa B (NFκB), interferon regulatory factor 3 (IRF3)) traverse the nuclear membrane and induce related genes by adhering to promotor regions of deoxyribonucleic 
acid (DNA). NfκB activity is inhibited by the most‐studied heat‐shock protein HSP70, which, thus,  diminishes the inflammatory response. HSP70 reduces the damage caused by excessive 
inflammation by decreasing apoptosis and preserving cell proteins [16].
Significant information has been obtained with the study of inflammatory processes, espe-
cially those induced by Gram‐negative bacteria. Septic shock occurs via similar mechanisms 
with Gram‐positive organisms. Here, instead of lipopolysaccharide, which is found in abun-
dance in Gram‐negative organisms, less potent cell wall molecules, such as peptidoglycan 
and teicoic acid, cause similar inflammatory responses.
Gram‐negative bacteria have a thin cell wall made up of a single layer of peptidoglycan, out 
of which there is a cell membrane consisting of lipopolysaccharide, which is a strong stimula-
tor of immune response. The lipopolysaccharide molecule has three main components [17]:
1. Lipid A is responsible for the biological activity of endotoxin. Its structure is almost the 
same in different strains.
2. Core polysaccharide is made up of oligosaccharides, but its structure is highly diverse 
among species, even within strains.
3. Oligosaccharide side chains vary among strains. It consists of repeating units (e.g., 40 
repetitions in O antigen) and is the moiety which provides the O antigen its antigenic 
specificity.
Lipopolysaccharide first binds to lipopolysaccharide‐binding protein (LBP) in plasma. LBP‐
lipopolysaccharide complex binds to CD14 molecule on the plasma membrane. This new 
complex binds to TRL4/MD (“myeloid differentiating factor”)‐2, which is also on the plasma 
Sepsis in Children
http://dx.doi.org/10.5772/68013
179
membrane [18]. This structure, activating various protein kinases, as outlined above, causes 
cytokine release when the end products bind to promotor regions on DNA [19].
There are countless cytokines playing roles in sepsis and septic shock. These mediators, caus-
ing release of each other, create an enormous mediator cascade. The mediator cascade is initi-
ated by the stimulation of tumor necrosis factor (TNF) (cachectin) production by stimulators 
like lipopolysaccharide, C5a, viruses, and enterotoxins. TNF appears to be the main cytokine 
initiating and playing a pivotal role in the progression of the mediator cascade. TNF, released 
from many cells, such as monocytes, macrophages, natural killer cells, microglial cells, and 
hepatic Kupfer cells, causes countless mediators (e.g., interleukin(IL)‐1β, IL‐6, eicosanoids, 
platelet activation factor) to spill into blood in an uncontrolled manner resulting in a very 
severe inflammatory response and endothelial damage. However, there are many cytokines, 
the productions of which do not necessitate the presence of TNF [20]. As a consequence of this 
process, typical signs of endotoxic shock will show up. Some of the cytokines released (e.g., 
TNF‐α, IL‐1, and IL‐6) cause free oxygen radical and protease release from other immune 
system cells, such as neutrophils, prostanoids leukotrienes, thromboxanes, nitric oxide, and 
endothelin from endothelial cells. Some of these substances are useful in killing bacteria but 
some (e.g., nitric oxide) are known to cause mitochondrial dysfunction by deactivating the 
catecholamines in the circulation. Mediators, whose release is induced by lipopolysaccharide, 
increase nitric oxide synthase II production and thus nitric oxide (endothelial‐origin relaxation 
factor) production. Nitric oxide is a potent vasodilator and is the primary substance respon-
sible for the hypotension in septic shock. Besides, nitric oxide causes vasodilation, which in 
turn causes diminished perfusion pressure in capillary network and blood flow by opening 
collateral channels. Decreased capillary flow results in organ hypoxia despite high blood flow 
because of vasodilation.
We have enough knowledge on how sepsis and septic shock develop, but it is surprising 
that only a few histopathologic changes concerning cell death are present in patients who 
have died of severe sepsis. Apart from cellular apoptosis in spleen and intestines, myopathic 
changes in skeletal muscle, and changes in vascular morphology in meningococcal sepsis, 
there is no serious sign of necrosis in main organs.
Then, studies have concentrated on microcirculation and mitochondrial dysfunction, and 
theories on how adenosine triphosphate (ATP) production can decrease under normal, even 
supranormal oxygen partial pressures, have been put forward. These theories include dimin-
ished pyruvate entry into tricarboxylic acid cycle, activation of poly‐(ADP‐ribose) polymerase, 
and uncoupling of oxidation from phosphorylation. Another cause of tissue hypoxia is nitric 
oxide’s combining with free oxygen radicals (O2−) to form peroxynitrite (ONOO−) resulting in reversible or irreversible binding of these three substances to proteins in the electron transport 
chain, such as succinate dehydrogenase and cytochrome c oxidase. As a result, ATP produc-
tion decreases, being unable to meet the needs of the energy‐consuming cell, and cell death 
takes place. This process accounts for the unexpectedly few histopathologic changes in autop-
sies. Complement system is activated through contact with bacterial molecules or binding of 
proteins, such as antibody or mannose‐binding lectin, to these molecules. Complements like 
C3b and C5a cause migration of leukocytes and increase inflammation [11].
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The balance between thrombogenesis and thrombolysis has been disrupted in sepsis. There 
is endothelial damage due to direct effect of microorganisms, cytokines, and fibrin deposition 
triggered by endothelial dysfunction. As a result of this, a process of simultaneous thrombo-
ses and bleedings, which is known as consumption coagulopathy or disseminated intravascu-
lar coagulation (DIC), develops. DIC is more frequently encountered in Gram‐negative sepsis 
(e.g., meningococcal sepsis) than in Gram‐positive sepsis. The most common complications of 
DIC are thromboses of great vessels, liver infarction, acute renal failure, cerebral hemorrhage, 
and cerebral infarction [21].
4.3. Cytokines as sepsis biomarkers
TNF, IL‐1b, and IL‐6 are the first cytokines to regulate the initial response of the innate 
immune system. TNF and IL‐1b activate endothelial cells and attract the granulocytes in cir-
culation to inflammation site. TNF and IL‐1b cause fever and other systemic signs by entering 
the circulation. IL‐6 increases the production of what is known as acute phase proteins (e.g., 
C‐reactive protein) in liver and more granulocytes in bone marrow. As can easily be seen, 
TNF, IL‐1b, and IL‐6 are responsible for the formation of SIRS and could be thought of being 
used as sepsis biomarkers [22].
TNF and IL‐1b concentrations increase in endotoxin‐associated Gram‐negative sepsis. TNF 
or IL‐1b administration to laboratory animals is as effective in the formation of septic shock 
as the endotoxin itself, but in clinical studies, TNF and IL‐1b could not be used as sepsis bio-
markers because
• TNF concentrations before anti‐TNF antibody treatment do not affect the outcome.
• IL‐1b does not rise as TNF does.
Of the three cytokines mentioned above, IL‐6 has attracted the most attention. The causes of 
this include
• The role of IL‐1b, IL‐1a, and the receptor antagonist of IL‐1 in the development of sepsis is 
debated [22].
• The relatively higher reliability of measurement of the plasma concentration of IL‐6.
• The usability of IL‐6 in the diagnosis and treatment of autoimmune rheumatologic diseases.
• The availability of commercial immunoassay kits, contrary to TNF and IL‐1b.
Nevertheless exactly as in TNF and IL‐1b, IL‐6 is not specific to sepsis and its role as sepsis 
biomarker is prognostic, rather than diagnostic. In many studies, rise in IL‐6 concentration is 
associated with higher mortality. This characteristic can be used to detect patients who may 
benefit from therapy [22].
Since the clinical signs of sepsis in neonates are very subtle and nonspecific, predictive bio-
markers are needed, particularly in economically developing countries, where the incidence, 
morbidity, and mortality of early neonatal sepsis (ENS) (sepsis diagnosed less than 72 h after 
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birth) are particularly high. Evidence published to date is still far from convincing the physi-
cian to use procalcitonin as a biomarker for routine use in clinical practice as a risk stratifier 
and a prognostic predictor or even to guide the duration of antibiotic treatment and bedside 
decision making [23]. The results of a new study by He et al. indicate that elevated IL‐27 
strongly correlates with ENS and may provide additional diagnostic value along with pro-
calcitonin [24].
The usage of IL‐6 and LBP in pediatrics is also promising. In newborns with late sepsis risk, 
IL‐6 rises 48 h before bacterial sepsis becomes clinically manifest [25]. Initial high IL‐6 con-
centrations predict future septic shock in hospitalized children [26]. Initial high IL‐6 concen-
trations foretell high risk of septic shock and mortality in pediatric burn patients [27]. LBP 
points to invasive bacterial infections and bacterial infections in children and newborns over 
28 weeks of gestational age, respectively [28–30]. LBP can differentiate between SIRS and ENS 
in newborns within the first 48 h of their lives [30].
While homing chemokines serve to regulate adaptive immune system, especially in second-
ary lymphoid tissue, proinflammatory chemokines attract granulocytes and monocytes to the 
site of inflammation and promote their extravasation. Chemokines, thanks to these proper-
ties, can be used as biomarkers in sepsis, and some of them have been shown to be superior to 
IL‐6 in that aspect. Examples are IL‐8 (in the diagnosis of sepsis) and monocyte chemoattrac-
tant protein (MCP)‐1 (in the determination of sepsis mortality) [31]. According to the results 
of a study, among 17 cytokines (IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12, IL‐13, 
IL‐17, interferon‐γ, granulocyte colony‐stimulating factor, granulocyte‐macrophage colony‐
stimulating factor, MCP‐1, macrophage inflammatory protein‐1, and TNF‐α), the cytokines 
most closely associated with organ dysfunction within 24 h are IL‐8 and MCP‐1 [31]. As yet, a 
cytokine which is uniquely associated with severe sepsis and septic shock and can be used as 
a biomarker has not been discovered [32].
4.4. Effect of cytokine storm on tissues and organs
• Cardiovascular system
Myocardium is depressed in septic shock. The reason for this depression is not hypo-
perfusion, but depressing cytokines like TNF and IL‐1β in the circulation. Ventricules 
dilate and ejection fraction drops. As a result, hypoperfusion ensues in peripheral tis-
sues. Peripheral hypoperfusion and hypoxia lead to overproduction of lactic acid, which 
is another myocardial depressor. This chain of events persists as a vicious cycle [21].
• Respiratory system
Alveoli are diffusely damaged because of circulating endotoxins. In the exudative phase 
of this damage, proteinaceous edema fluid accumulates in alveoli, and type I epithelial 
cells are injured. In this clinical picture, which is also known as shock lung, alveolar 
collapse, hemorrhage, edema, hyaline membrane formation, which is made up of fibrin 
and necrotic epithelial cells on epithelial surfaces of respiratory bronchioles and alve-
olar ducti, and neutrophil accumulation in alveolar capillaries occur. Unless treated, 
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severe pulmonary edema develops despite low central venous pressure, and as a result, 
 ventilation‐perfusion mismatch ensues. This clinical picture is called ARDS. In the 
regeneration phase, healing occurs via return to normal structure or pulmonary fibrosis. 
Lost type 1 cells are replaced by proliferating type 2 cells. Superimposing infections and 
barotrauma due to mechanical ventilation worsen respiratory system functions [21].
• Kidneys
Nitric oxide disrupts blood distribution in renal medulla and cortex. With the effect of 
nitric oxide and cytokines, renal tubule function, which requires high energy input, dete-
riorates due to decreasing ATP production. As a consequence of hypotension, increase 
in the release of endothelin, which is a vasopressor hormone, and activation of renin‐
angiotensin‐aldosterone system pave the way to sodium and water retention, which 
makes a ground for renal failure. Neutrophil adhesion and microthrombi further dimin-
ish the glomerular filtration rate. The question of why renal failure in sepsis, despite 
anuria and despite its presence even in patients who die of sepsis, can develop without 
acute tubular necrosis and why it takes renal function so long (months) to return to nor-
mal while systemic inflammation has already disappeared and circulatory function has 
returned to normal still stands as an enigma and awaits to be elucidated [11, 21].
• Central and peripheral nervous system
The most important one among the effects of sepsis on central nervous system is sepsis‐
related encephalopathy and critical illness polyneuropathy. The causes of encephalopa-
thy include disruption of blood‐brain barrier, coagulopathy‐related cerebral hemorrhage, 
microinfarctions, hypoxic‐ischemic encephalopathy, metastatic brain abscesses, menin-
gitis, and cytokine storm. While this clinical entity, which manifest itself with delirium 
and confusion, is often reversible, it may lead to self‐mutilism of the patient in intensive 
care and development of cognitive and behavioral dysfunction in the long term.
The diagnosis of this clinical picture, which manifests itself also with flaccid paralysis 
and loss of deep tendon reflexes, is usually made only during or after separation of the 
patient from ventilator due to encephalopathy, administration of neuromuscular drugs, 
and the unfavorable general situation of the patient. Prognosis varies according to the 
severity of illness and patient’s age. Muscle weakness may last for months [21].
• Gastrointestinal system
Gastrointestinal system is negatively affected by sepsis due to hypoperfusion. Gastro‐
intestinal bleeding may ensue as a consequence of splanchnic hypoperfusion, increase in 
intestinal permeability, bacterial translocation, stress ulcers, and coagulopathy.
Although liver is relatively resistant to sepsis, transaminase elevation, peribiliary infarc-
tions, and cholestatic jaundice may ensue as a result of hypotension [21].
• Immune system
Although an immunologic hyperreaction itself, sepsis further disrupts the integrity of the 
immune system. In survivors of sepsis, mortality rate is higher in the  following  several 
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years than that in normal population, which can be attributed to a vague immune dis-
order with cytokines and chemokines [21, 33]. Overproduction of anti‐inflammatory 
cytokines may be a cause of immune deficiency in sepsis, but there is no evidence that 
the abundance of anti‐inflammatory cytokines (such as IL‐1 receptor antagonist and 
soluble TNF receptors) in the environment is sufficient for putting away the effects of 
proinflammatory cytokines [20].
• Extremities
A clinical picture of skin bleeding and necrosis due to microvascular thrombi and subse-
quent perivascular hemorrhage may develop, especially in the presence of disseminated 
intravascular coagulation. This is called purpura fulminans (PF). Although most fre-
quently encountered in N. meningitidis bacteremia, PF may ensue in bloodstream infec-
tions due to S. pneumoniae and capsulated microorganisms of any kind. In addition to 
necroses in PF, vasoconstriction in sepsis may be severe enough to cause infarctions of 
fingers and autoamputation. Vasopressor drugs, if administered without fluid resuscita-
tion, increase the risk for this complication [21, 33].
• Mental status
Psychological disorders, such as posttraumatic stress disorder (in 20% of ARDS patients), 
depression, panic attack, public isolation, inability to stay alone or in crowded areas, and 
decrease in sexual activity, are seen frequently in survivors of sepsis [21].
4.5. The role of gene polymorphisms in predisposition to sepsis
Whether there is an association between the severity of sepsis and septic shock and cytokine 
gene polymorphisms is an important field of study. Such a connection could not be shown 
with IL‐1, IL‐1 receptor antagonist, and IL‐10 genes. It has been postulated that TNF2, being 
a rare TNF gene (adenine at −308 position), may be associated with high promoter activity, 
but no elevation in the prevalence of TNF2 allele in patients having frequent attacks of severe 
sepsis and infections due to Gram‐negative organisms has been noted. There is a publication 
stating that rare Arg753Gln mutation of TLR2 renders individuals prone to staphylococcal 
sepsis [33]. Single‐nucleotide polymorphism in IL‐1β gene was found associated with higher 
mortality [34].
5. Medical history
In sepsis, complaints leading to the child being brought to the physician vary according to the 
source of infection or SIRS. Fever, hypothermia tachypnea, stomach ache, vomiting, diarrhea, 
clouding of consciousness, or several of these may be present in the child. Features in the his-
tory such as the child’s immunization status, past infections, and attending daycare should 
be taken into notice [35].
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6. Physical examination
Fever or hypothermia (core body temperature <36°C) may be observed [5]. Abnormalities 
in other vital signs may also be detected. Normal limits of vital signs according to age are 
depicted in Table 2 [36].
Shock may not be present in sepsis. Hypotension is not a prerequisite for shock. Mottled skin 
and prolongation of capillary refill time may help the physician recognize septic shock before 
hypotension emerges [2, 5].
7. Laboratory tests
In a child suspected of having sepsis, the following tests may be ordered: complete blood 
count (always with differentials), a reasonable metabolic panel (electrolytes, glucose, liver 
function tests, and albumin), serum lactate, arterial blood gases, coagulation studies, amylase, 
lipase, urinalysis, sputum culture, and Gram stain [35]. Leukocytosis or leukopenia may be 
present in children with sepsis (Table 3) [2].
Antibiotics should be started after blood and other cultures being drawn unless a delay of lon-
ger than 45 min is expected because of this process. According to the results of a recent study, 
the diagnosis of pediatric septicemia through BACTEC 9240 is quicker with high yield and 
great sensitivity compared to the conventional technique [37]. Blood cultures are recommended 
to be taken from a peripheral vein and a catheter, which has been in place for more than 48 h 
into a set of aerobic and anaerobic bottles and as at least two sets. In case the volume of the 
blood is insufficient, the sensitivity of the blood culture will decrease, and vice versa [38, 39]. 
The author suggests that anaerobic blood cultures not be taken from children routinely, since
• The volume of blood that can be taken from children is limited.
• True anaerobic blood stream infections are rare (<5%) in children.
• Instead of sets consisting of one aerobic and one anaerobic bottle, selective culture for an-
aerobic organisms with two aerobic bottles yields better results (6% more positives).
Age group Bradycardia (pulse/
min)
Tachycardia (pulse/
min)
Respiratory rate 
(respirations/min)
Systolic blood 
pressure (mmHg)
0 day to 1 week <100 <180 >50 <65
1 week to 1 month <100 <180 >40 <75
1 month to 1 year <90 <180 >34 <100
2–5 years <80 <140 >22 <94
6–12 years <70 <130 >18 <105
13–18 years <60 <110 >14 <117
Table 2. Normal of vital signs according to age [36].
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• Since sensitivity patterns of anaerobes are well known, they can be covered effectively with 
empirical therapy.
Even if anaerobic blood cultures are to be drawn, the indications should be limited to risky 
situations as below [40–42]:
• Children displaying abnormal abdominal symptoms and signs.
• Children with sacral decubitus ulcers or cellulitis.
• Patients with poor oral hygiene, severe oral mucositis, or chronic sinusitis.
• Neutropenic children receiving high‐dose corticosteroid therapy, which may mask abdom-
inal symptoms.
• Children with sickle cell disease.
• Infants of mothers with prolonged rupture of membranes or chorioamnionitis.
• Children thought to have bacteremia due to a human bite or crushing trauma.
When clinically indicated, cultures may be taken from urine, cerebrospinal fluid, wounds, 
respiratory secretions, and other body fluids. Most accurate results will probably be obtained 
with double quantitative blood cultures in case of an intravascular device‐related blood-
stream infection. Mannan, antimannan, and 1,3 beta‐D‐glucan tests may be used if invasive 
candidiasis is suspected. Imaging techniques are very useful to delineate the foci of infection 
and to decide whether the patient’s condition is suitable for transport [5].
8. Diagnosis and differential diagnosis
Risk‐scoring systems may guide the physician in deciding the presence of a serious bacterial 
infection [43]. As mentioned above, if a probable or proven infection is present with SIRS, 
the child is in sepsis. Sepsis should be differentiated from other causes of SIRS (e.g., trauma, 
burn, acute pancreatitis, drug reaction (acetaminophen, cytarabine, IL‐2)) and hypotension 
Age group Leukocyte count (×103/μL)
0–7 days >34
1 week to 1 month >19.5 or <5
1 month to 1 year >17.5 or <5
2–5 years >15.5 or <6
6–12 years >13.5 or <4.5
12–18 years >11 or <4.5
Table 3. Leukocyte counts according to age [2].
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(e.g., hypovolemic shock, cardiogenic shock, neurogenic shock, and adrenocortical insuffi-
ciency) [4, 44–46]. The value of procalcitonin and other biomarkers in the differential diagno-
sis of sepsis is under investigation [5].
9. Management
The management of severe sepsis and septic shock involves the following phases:
9.1. Hemodynamic support
Hemodynamic support should be started promptly without waiting for the intensive care 
admission. A protocol on recognizing septic shock in emergency ward may shorten the time 
that is passed for the initiation of appropriate therapy [47]. Although central venous line is 
preferred, fluids may be given through peripheral veins or via intraosseous route if a central 
venous catheter is not present or cannot be placed [5, 48]. Initial recommended fluid is crys-
talloid (e.g., normal saline) in boli of 20 mL/kg, each administered in 5–10 min. It should be 
kept in mind that mortality in children may be reduced if albumin is used in the initial fluid 
[49]. These crystalloids or colloid boli are continued until the perfusion returns to normal and 
the total given fluid volume reaches 60 mL/kg or more unless hepatomegaly or rales develop 
[48]. It is imperative that fluid resuscitation be given as rapidly as possible and not sparingly. 
The mortality in children who were given a total of more than 40 mL/kg is about 40% lower 
than those given a total of less than 20 mL/kg. The duration of intensive care and hospital 
stay become shorter (2–3 days) in patients given 60 mL/kg of fluid in the first 60 min than 
those who are not [50–52]. Inotropic support is recommended instead of fluid replacement 
if hepatomegaly or crackles are present. If the child has severe hemolytic anemia and blood 
pressure is normal, blood transfusion should be preferred to crystalloid or albumin boli [5].
For children in respiratory distress or hypoxia, oxygen should be administered with a mask; 
thereafter, if needed and if possible, high‐flow oxygen through nasal cannula or nasopha-
ryngeal continuous positive air pressure (CPAP) may be carried out [5, 48]. An adequate car-
diovascular resuscitation reduces the likelihood of cardiovascular instability if mechanical 
ventilation is needed [5].
In the early management (in the first hour and in emergency ward), clinical goals for the sep-
tic shock patient are the following:
• Bring the capillary refill time back to 2 s or less.
• Provide blood pressure normal for age.
• Obtain a normal pulse and heart rate by removing the difference between central and pe-
ripheral pulses.
• Warm the extremities.
• Raise the urine output above 1 mL/kg/h.
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• Restore hypoglycemia and hypocalcemia back to normal.
• Restore mental status.
Antibiotics should have been started meanwhile [5, 48, 53].
Goals to be realized by invasive monitorization of the patient are as follows:
• Central venous oxygen saturation of 70% or above and
• Cardiac index of 3.3–6 L/min/m2 [5, 54]
9.2. Inotropes, vasopressors, and vasodilators
The patients whose initial fluid therapy has been completed in 10–15 min and who are unre-
sponsive to this therapy (twice crystalloid or colloid boli) should have been started inotrope 
support at about 15th min of management through a peripheral vein if necessary until central 
venous route is assured [5, 55]. The goals at this stage of the management are as follows [5]:
• Normal perfusion pressure (mean arterial pressure, central venous pressure): 55 mmHg 
for term newborns, 60 mmHg for children 1 month to 1 year of age, 65 mmHg for children 
aged 1–15 years.
• Central venous oxygen saturation (ScvO2) = 70%.
• Cardiac index = 3.3–6 L/min/m2.
In cold shock with normal blood pressure but abnormal capillary refill time (>2 s), the dosage 
of dopamine given through central vein can be increased to 10 μg/kg/min. If shock is refrac-
tory to dopamine, epinephrine (0.05–3 μg/kg/min) should be given; ScvO2 and hemoglobin (Hb) should be kept above 70% and 10 g/dL, respectively. If ScvO2 persists below 70%, a vaso-dilator, such as milrinone and imrinone, should be added to therapy; levosimendan should 
be considered to be started [5, 48].
In cold shock with low blood pressure, ScvO2 and Hb should be kept above 70% and 10 g/dL, respectively. If shock is refractory to dopamine, epinephrine (0.05–3 μg/kg/min) should be 
given; if hypotension persists, norepinephrine should be started. If ScvO2 is still below 70%, dobutamine, milrinone, enoksimone, or levosimendan should be considered [5, 48].
In warm shock with low blood pressure, the rate of norepinephrine should be adjusted such that 
ScvO2 stays above 70%. If hypotension persists, vasopressin, terlipressin, or angiotensin should be considered. If ScvO2 is still below 70%, low‐dose epinephrine should be considered [5, 48].
In some patients, in whom systemic vascular resistance is very low despite norepinephrine 
administration, vasopressin, and terlipressin were used, but no benefit from these drugs has 
been shown in randomized studies [56–60]. In patients with low cardiac output, but high 
systemic vascular resistance, vasodilators such as
• Calcium sensitizer (levosimendan).
• Type III phosphodiesterase inhibitors (amrinone, enoximone, or milrinone).
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• Nitrovasodilators.
• Prostacyclin.
• Fenoldopam.
• Pentoxifylline.
have been proposed in addition to inotropes [5].
If no response is taken with this therapy, the case is accepted as catecholamine‐resistant 
shock, and the patient should be started hydrocortisone if at risk for absolute adrenal insuf-
ficiency [5, 48].
If catecholamine‐resistant shock persists, pneumothorax, pericardial effusion, and high intraab-
dominal pressure should be excluded or corrected if present; pulmonary artery catheter, pulse 
contour cardiac output catheter, and femoral artery thermodilution catheter should be used 
or Doppler ultrasonography should be considered to receive some guidance on therapy [48].
If, despite all these measures, shock cannot be taken under control, extracorporeal membrane 
oxygenation (ECMO) should be considered [5, 61, 62].
9.3. Antimicrobial therapy
After severe sepsis is recognized, antibiotics should be started in the first hour, even in the first 
15 min if possible. Cultures should be taken before initializing therapy if feasible, but therapy 
should not be delayed for this reason. The choice of antibiotic should be in accordance with 
endemic or epidemic data. Intramuscular or oral route may be used until intravenous access 
is made. In toxic shock syndromes with refractory hypotension, clindamycin and antitoxin 
are recommended. The management of Clostridium difficile colitis is preferentially carried out 
with enteral antibiotics; vancomycin should be used for severe colitis. Antimicrobial therapy 
should continually be reevaluated with regard to deescalation [5].
Combination empirical therapy is recommended for neutropenic patients with severe sepsis 
and in places where difficult‐to‐treat organisms, such as Acinetobacter and Pseudomonas, are 
prevalent. This therapy should be in the form of a wide‐spectrum beta‐lactam antibiotic + an 
aminoglycoside/quinolone in places where the risk of infection due to Pseudomonas is high. 
If the prevalence of S. pneumoniae is high, a beta‐lactam + macrolide combination is recom-
mended. Combination therapy should be of short duration (3–5 days or less) according to 
antibiotic‐sensitivity results [5].
The duration of antimicrobial therapy should be limited to 7–10 days unless
• The response is slow,
• The infection focus is undrainable,
• S. aureus bacteremia is present,
• Some fungus or virus infections are present,
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• An immunologic disorder with neutropenia is present, or
• Pneumonia due to Pseudomonas spp. or other Gram‐negative rods is present [5, 63].
Narrowing the antimicrobial spectrum and shortening the duration of antimicrobial therapy 
would prevent superinfections due to other agents, such as Candida spp., C. difficile, and van-
comycin‐resistant Enterococcus faecium [5].
Antiviral therapy should be started in sepsis or septic shock due to viruses. Antimicrobial 
therapy should be stopped in case that the cause of sepsis was detected as something other 
than infection. The removal of infected intravascular devices, especially central venous cathe-
ters, if possible and if preferred to antibiotic lock methods, will reduce mortality and increase 
the chances that the infection will be cured [5, 64].
9.4. Transfusions
If superior vena cava oxygen saturation is low (<70%), Hb concentration should be maintained 
at 10 g/dL. After hypoxemia and shock subside, the goal for Hb should be over 7 g/dL. Higher 
concentrations may be needed if acute bleeding, severe hypoxemia, or ischemic heart disease is 
present [5, 65, 66].
Platelet transfusion is indicated if the platelet count is
• Below 10,000/μL without a detectable bleeding.
• Below 20,000/μL if the patient has significant bleeding risk.
• Below 50,000/μL in the presence of active bleeding or in situations requiring either surgical 
or invasive procedures.
Plasma therapy should be brought to the agenda in case of thrombotic purpura situa-
tions, such as progressive disseminated intravascular coagulation due to sepsis, secondary 
thrombotic microangiopathy, and thrombotic thrombocytopenic purpura. In the absence of 
planned invasive intervention or bleeding, antithrombin therapy, erythropoietin adminis-
tration for sepsis‐associated anemia, and fresh‐frozen plasma therapy should be avoided.
9.5. Corticosteroids
Hydrocortisone should be given to children with severe sepsis only in the presence of suspected 
or proven adrenal insufficiency, because there are publications both favoring (for reduction in 
mortality) and discouraging (for increasing mortality) its use [5, 67, 68]. Risk factors for adre-
nal insufficiency include severe septic shock with purpura, steroid use for chronic illness, and 
hypophysis or adrenal gland abnormalities. Hydrocortisone infusion is started with the dosage 
of 50 mg/m2/24, which may be needed to be increased up to 50 mg/kg/day in a short time. The 
measurement of baseline serum cortisol concentration may be useful at the onset of therapy [5].
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9.6. Miscellaneous recommendations
In ARDS, tidal volumes exceeding 10 mL/kg should be avoided. Plateau pressure, arterial 
pH, and arterial partial oxygen pressure should be maintained at 30 cmH2O or below, between 7.3–7.45 and 60–80 Torr (8–10.7 kPa), respectively. The Hb goal of 10 g/dL in 
unstable patients should be taken as 7 g/dL after recovery from shock and deep hypoxia 
[69].
Water retention in patients recovering from shock should be treated with diuretics. If this 
fails, continuous venovenous hemofiltration or intermittent dialysis should be carried out in 
order to prevent water retention of more than 10% of the body weight [5].
In children with septic shock, glucose concentration should be maintained below 180 mg/dL 
since concentrations of 178 mg/dL and over are associated with higher mortality. In newborns 
and children, insulin therapy should be given along with glucose infusion, the rate of which 
should be 4–6 mg/kg/min (6–8 mg/kg/min in newborns). The alternative is giving mainte-
nance fluids prepared with 10% dextrose in water [5, 70].
Although no sedative or sedation protocol is recommended for patients with sepsis and 
mechanical ventilation support, long‐term propofol should be avoided in children below 
3 years for its association with fatal metabolic acidosis. Etodomidate and dexmedetomi-
dine should also be avoided due to its inhibitory effect on adrenal axis and sympathetic 
nervous system, the integrity of which is essential for hemodynamic stability in septic 
shock [5].
Enteral route should be preferred to parenteral route in nutrition. Glucose requirements of 
newborns and children can be met with sodium‐containing fluids prepared with 10% dex-
trose in water and administered at maintenance rate.
10. Prognosis
Hospital mortality of pediatric sepsis is 2–10% [5]. In United States, hospital mortality in 
severe sepsis has declined from 10% in 1995 to 4% in 2003 [71, 72]; this is probably because 
septic shock is increasingly recognized more readily and earlier in the course and treated 
more aggressively [73].
Seven and six percent of children who are discharged from hospital after surviving postneo-
natal sepsis die within 28 days and afterward, respectively (early and late mortality). About 
half of those who survive these 28 days are rehospitalized at least once. Comorbidity is 
important in the development and late mortality of and rehospitalization in pediatric sepsis 
[74, 75].
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11. Conclusion
As sepsis in children continues to take lives of children, especially in economically developing 
countries, it will continue to be the focus of attention for physicians, scientists, and the public. 
Although there are a few newer antibiotics in the pipeline, other novel therapies hold promise 
for overcoming this “cytokine storm disease” in near future.
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